Edition:
India

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

1.99USD
17 Jan 2018
Change (% chg)

$-0.03 (-1.49%)
Prev Close
$2.02
Open
$2.04
Day's High
$2.05
Day's Low
$1.96
Volume
251,349
Avg. Vol
270,551
52-wk High
$3.14
52-wk Low
$1.75

Chart for

About

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry,... (more)

Overall

Beta: 2.64
Market Cap(Mil.): $366.19
Shares Outstanding(Mil.): 159.21
Dividend: --
Yield (%): --

Financials

BRIEF-Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019

* GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​ Source text (http://bit.ly/2COKF0K) Further company coverage:

08 Jan 2018

BRIEF-Geron Corp Q3 loss per share $0.04

* Geron Corporation reports third quarter 2017 financial results

02 Nov 2017

BRIEF-Geron announces fast track designation grant for imetelstat

* Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes

31 Oct 2017

BRIEF-Geron Q2 loss per share $0.04

* Geron Corporation reports second quarter 2017 financial results

10 Aug 2017

BRIEF-Geron provides updates to imetelstat clinical development

* Expects imbark protocol-specified primary analysis to begin no later than q3 of 2018 Source text for Eikon: Further company coverage:

01 Aug 2017

Earnings vs. Estimates